Lifeboat Foundation

With a seemingly infinite amount of knowledge available to us at the tap of a smartphone, we all take digital information for granted. But when it can be replicated at zero cost, how do the economic laws of supply and demand work, especially in the context of using digital currency?

University of Arizona Project Nautilus aims to create a space telescope that can survey transiting exo-earths for biosignatures 1000 light years away.

John Wallace

https://www.linkedin.com/pulse/current-state-longevity-scien…colangelo/

Newly discovered life forms inside our bodies profoundly affect our health – and provide a glimpse of the vast and mysterious biological “dark matter” within us.

Expanded genetic alphabet could allow for the production of new protein-based drugs.

A study of 8,000 years of genetics from Spain and Portugal yields a surprisingly complex picture of the inhabitants’ ancestry.

A common concern about life extension is overpopulation, the idea that there are too many people in the world. Are we really headed for a global overpopulation meltdown, as some people believe? The United Nations’ World Population Prospects 2019 report suggests that while the global population will continue to rise for the next few decades, ultimately, that rise will plateau.

First things first: it’s population growth, not overpopulation

Whenever the topic of defeating age-related diseases comes up, there is inevitably someone who will cite overpopulation as an objection to healthy life extension and a reason why we should continue to let people become sick and die of diseases that science may be able to cure in the coming decades.

Two known gene mutations induce pathways that enhance pancreatic cancer’s ability to invade tissues and evade the immune system. Researchers report the molecular details of this process, providing insights into druggable targets for immunotherapies.

Mutations in the genes KRAS and TP53 are closely linked to pancreatic ductal adenocarcinoma, by far the most common type of pancreatic cancer. Pancreatic cancers are often already malignant when diagnosed, making its five-year survival rate extremely low—less than ten percent. So, understanding how it evolves at the molecular level could help anti-cancer drug development.

Hisataka Sabe of Hokkaido University and colleagues in Japan conducted tests in human cancer cells and in mouse models of the disease to investigate the roles of KRAS and TP53 gene mutations in pancreatic ductal adenocarcinoma. The study was published in the journal Proceedings of the National Academy of Sciences (PNAS).